Re-analysis of LEADER trial shows sustained liraglutide exposure reduces 3.5-year cardiovascular risk by 1.1%
Background
The LEADER trial initially established liraglutide as a beneficial treatment for type 2 diabetes patients, demonstrating significant cardiovascular (CV) risk reduction. However, its original per-protocol analysis, which conditioned on post-baseline adherence, presented a methodological challenge by lacking a clearly defined estimand. This approach made it difficult to precisely quantify the effect of consistent drug exposure. Understanding the true impact of sustained liraglutide treatment on cardiovascular outcomes in a real-world context, where adherence can vary, is crucial for refining clinical guidelines and future trial designs. This re-analysis addresses this gap by applying advanced statistical methods to account for non-adherence.
Study Design
Researchers re-analyzed data from the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, which originally randomized patients with diabetes to liraglutide or placebo. This study focused on defining an estimand for sustained treatment analysis using a roadmap of targeting learning. The effect was estimated with longitudinal targeted minimum loss-based estimation, a method designed to account for protocol deviations and censoring by utilizing post-baseline confounders. The re-analysis compared the estimated 3.5-year risks of the primary composite outcome (myocardial infarction, stroke, or cardiovascular mortality) and several secondary outcomes against the original intention-to-treat (ITT) analysis.
Results
The original intention-to-treat (ITT) analysis estimated 3.5-year risks for the primary composite outcome at 11.8% (95% confidence interval: 10.8 to 12.8) in the liraglutide arm and 13.3% (95% confidence interval: 12.3 to 14.3) in the placebo arm, showing a risk difference of 1.5% (95% confidence interval: 0.1 to 2.9). > Accounting for post-baseline confounders, the sustained treatment analysis estimated 3.5-year risks of 11.4% (95% confidence interval: 10.4 to 12.5) for sustained exposure to liraglutide versus 12.6% (95% confidence interval: 11.5 to 13.7) for sustained exposure to placebo, yielding a risk difference of 1.1% (95% confidence interval: -0.4 to 2.6). Crucially, the sustained exposure to liraglutide showed no statistically significant difference compared with sustained exposure to placebo for any secondary outcomes at 3.5 years, suggesting the primary benefit is concentrated on the composite CV endpoint.
Why It Matters
This re-analysis provides a more robust estimate of liraglutide's cardiovascular benefits by rigorously accounting for non-adherence, a common challenge in long-term clinical trials. The findings reinforce that consistent liraglutide use offers a meaningful, albeit slightly smaller, reduction in major adverse cardiovascular events compared to the initial ITT analysis. This refined understanding can inform clinicians about the expected real-world efficacy of liraglutide when patients maintain adherence. For individuals using liraglutide, this underscores the importance of consistent dosing for maximizing cardiovascular protection. While not a new protocol, it strengthens the evidence base for sustained GLP-1R agonist therapy in type 2 diabetes patients at high CV risk, emphasizing the value of adherence in achieving therapeutic goals.